127 related articles for article (PubMed ID: 16246561)
1. Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile.
Ceccarelli SM; Pinard E; Stalder H; Alberati D
Bioorg Med Chem Lett; 2006 Jan; 16(2):354-7. PubMed ID: 16246561
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors.
Pinard E; Ceccarelli SM; Stalder H; Alberati D
Bioorg Med Chem Lett; 2006 Jan; 16(2):349-53. PubMed ID: 16246557
[TBL] [Abstract][Full Text] [Related]
3. 4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters.
Alberati D; Hainzl D; Jolidon S; Kurt A; Pinard E; Thomas AW; Zimmerli D
Bioorg Med Chem Lett; 2006 Aug; 16(16):4321-5. PubMed ID: 16762550
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2.
Caldwell JP; Matasi JJ; Fernandez X; McLeod RL; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2009 Feb; 19(4):1164-7. PubMed ID: 19147350
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability.
Alberati D; Hainzl D; Jolidon S; Krafft EA; Kurt A; Maier A; Pinard E; Thomas AW; Zimmerli D
Bioorg Med Chem Lett; 2006 Aug; 16(16):4311-5. PubMed ID: 16757170
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: achieving selectivity against the mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors.
Alberati D; Ceccarelli SM; Jolidon S; Krafft EA; Kurt A; Maier A; Pinard E; Stalder H; Studer D; Thomas AW; Zimmerli D
Bioorg Med Chem Lett; 2006 Aug; 16(16):4305-10. PubMed ID: 16762548
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.
Caldwell JP; Matasi JJ; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2281-4. PubMed ID: 17289383
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor.
Liu M; He L; Hu X; Liu P; Luo HB
Bioorg Med Chem Lett; 2010 Dec; 20(23):7004-10. PubMed ID: 20961754
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine.
Yoshizumi T; Miyazoe H; Ito H; Tsujita T; Takahashi H; Asai M; Ozaki S; Ohta H; Okamoto O
Bioorg Med Chem Lett; 2008 Jul; 18(13):3778-82. PubMed ID: 18515099
[TBL] [Abstract][Full Text] [Related]
11. Structural requirements of N-substituted spiropiperidine analogues as agonists of nociceptin/orphanin FQ receptor.
Bao P; Zhang X; Ren H; Li Y; Mu Z; Zhang S; Li G; Yang L
Int J Mol Sci; 2011; 12(12):8961-81. PubMed ID: 22272114
[TBL] [Abstract][Full Text] [Related]
12. C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.
Cueva JP; Roche C; Ostovar M; Kumar V; Clark MJ; Hillhouse TM; Lewis JW; Traynor JR; Husbands SM
J Med Chem; 2015 May; 58(10):4242-9. PubMed ID: 25898137
[TBL] [Abstract][Full Text] [Related]
13. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
Trapella C; Fischetti C; Pela' M; Lazzari I; Guerrini R; Calo' G; Rizzi A; Camarda V; Lambert DG; McDonald J; Regoli D; Salvadori S
Bioorg Med Chem; 2009 Jul; 17(14):5080-95. PubMed ID: 19527931
[TBL] [Abstract][Full Text] [Related]
15. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.
Chang SD; Mascarella SW; Spangler SM; Gurevich VV; Navarro HA; Carroll FI; Bruchas MR
Mol Pharmacol; 2015 Sep; 88(3):502-11. PubMed ID: 26134494
[TBL] [Abstract][Full Text] [Related]
17. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
18. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.
Röver S; Adam G; Cesura AM; Galley G; Jenck F; Monsma FJ; Wichmann J; Dautzenberg FM
J Med Chem; 2000 Apr; 43(7):1329-38. PubMed ID: 10753470
[TBL] [Abstract][Full Text] [Related]
19. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
[TBL] [Abstract][Full Text] [Related]
20. 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Trapella C; Chiou LC
Eur J Pharmacol; 2009 Mar; 606(1-3):84-9. PubMed ID: 19374842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
